FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034679752> ?p ?o ?g. }

• W2034679752 endingPage "1743" @default.
• W2034679752 startingPage "1737" @default.
• W2034679752 abstract "We evaluated pathologic and survival outcomes of GC (gemcitabine/cisplatin) and methotrexate/vinblastine/doxorubicin/cisplatin (M-VAC) neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). A retrospective analysis of prospectively collected data on 116 patients who received NAC (GC: n = 58; M-VAC: n = 58) before radical cystectomy and superextended pelvic lymph node dissection for clinical stage T2-4N0M0 bladder cancer was performed. The outcomes were complete response rate (CRR; pT0N0), partial response rate (PRR; pT0N0, pTaN0, pT1N0, or pTisN0), overall mortality (OM), and recurrence. The Kaplan-Meier method and multivariable Cox regression analysis were used to analyze OM. The cumulative incidence method and Fine and Gray's competing risk regression analysis were used to analyze recurrence. The median follow-up duration was 2.1 years for the GC group and 7.4 years for the M-VAC group (P < 0.001). There were no statistically significant differences between the GC and M-VAC groups with regard to CRR (27.3% vs. 17.1%, P = 0.419) or PRR (45.5% vs. 37.1%, P = 0.498). The predicted 5-year freedom from OM rate (P = 0.634) and cumulative incidence of recurrence rate (P = 0.891) did not differ between the GC and M-VAC groups. Multivariable analysis showed that there was no independent association between type of NAC and OM (P = 0.721) or recurrence (P = 0.065). Pathologic and survival outcomes did not differ in patients who received GC and M-VAC NAC. These data support the use of the GC regimen in the neoadjuvant setting." @default.
• W2034679752 created "2016-06-24" @default.
• W2034679752 creator A5029586660 @default.
• W2034679752 creator A5031088617 @default.
• W2034679752 creator A5046763596 @default.
• W2034679752 creator A5047940829 @default.
• W2034679752 creator A5049240288 @default.
• W2034679752 creator A5063174892 @default.
• W2034679752 creator A5067558680 @default.
• W2034679752 creator A5075516105 @default.
• W2034679752 creator A5084766370 @default.
• W2034679752 creator A5091696839 @default.
• W2034679752 date "2013-11-01" @default.
• W2034679752 modified "2023-10-17" @default.
• W2034679752 title "Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California" @default.
• W2034679752 cites W1513738801 @default.
• W2034679752 cites W1538189929 @default.
• W2034679752 cites W1554784429 @default.
• W2034679752 cites W1975918912 @default.
• W2034679752 cites W2029132015 @default.
• W2034679752 cites W2053249542 @default.
• W2034679752 cites W2054399970 @default.
• W2034679752 cites W2073804272 @default.
• W2034679752 cites W2099060071 @default.
• W2034679752 cites W2103257412 @default.
• W2034679752 cites W2113156769 @default.
• W2034679752 cites W2128042367 @default.
• W2034679752 cites W2135640630 @default.
• W2034679752 cites W2154121012 @default.
• W2034679752 cites W2160658069 @default.
• W2034679752 cites W2165948908 @default.
• W2034679752 doi "https://doi.org/10.1016/j.urolonc.2012.07.005" @default.
• W2034679752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23141776" @default.
• W2034679752 hasPublicationYear "2013" @default.
• W2034679752 type Work @default.
• W2034679752 sameAs 2034679752 @default.
• W2034679752 citedByCount "59" @default.
• W2034679752 countsByYear W20346797522013 @default.
• W2034679752 countsByYear W20346797522014 @default.
• W2034679752 countsByYear W20346797522015 @default.
• W2034679752 countsByYear W20346797522016 @default.
• W2034679752 countsByYear W20346797522017 @default.
• W2034679752 countsByYear W20346797522018 @default.
• W2034679752 countsByYear W20346797522019 @default.
• W2034679752 countsByYear W20346797522020 @default.
• W2034679752 countsByYear W20346797522021 @default.
• W2034679752 countsByYear W20346797522022 @default.
• W2034679752 countsByYear W20346797522023 @default.
• W2034679752 crossrefType "journal-article" @default.
• W2034679752 hasAuthorship W2034679752A5029586660 @default.
• W2034679752 hasAuthorship W2034679752A5031088617 @default.
• W2034679752 hasAuthorship W2034679752A5046763596 @default.
• W2034679752 hasAuthorship W2034679752A5047940829 @default.
• W2034679752 hasAuthorship W2034679752A5049240288 @default.
• W2034679752 hasAuthorship W2034679752A5063174892 @default.
• W2034679752 hasAuthorship W2034679752A5067558680 @default.
• W2034679752 hasAuthorship W2034679752A5075516105 @default.
• W2034679752 hasAuthorship W2034679752A5084766370 @default.
• W2034679752 hasAuthorship W2034679752A5091696839 @default.
• W2034679752 hasConcept C121608353 @default.
• W2034679752 hasConcept C126322002 @default.
• W2034679752 hasConcept C126894567 @default.
• W2034679752 hasConcept C141071460 @default.
• W2034679752 hasConcept C143998085 @default.
• W2034679752 hasConcept C167135981 @default.
• W2034679752 hasConcept C2775910329 @default.
• W2034679752 hasConcept C2776694085 @default.
• W2034679752 hasConcept C2777132456 @default.
• W2034679752 hasConcept C2778239845 @default.
• W2034679752 hasConcept C2780258809 @default.
• W2034679752 hasConcept C2780352672 @default.
• W2034679752 hasConcept C50382708 @default.
• W2034679752 hasConcept C71924100 @default.
• W2034679752 hasConcept C72563966 @default.
• W2034679752 hasConcept C88879693 @default.
• W2034679752 hasConcept C90924648 @default.
• W2034679752 hasConceptScore W2034679752C121608353 @default.
• W2034679752 hasConceptScore W2034679752C126322002 @default.
• W2034679752 hasConceptScore W2034679752C126894567 @default.
• W2034679752 hasConceptScore W2034679752C141071460 @default.
• W2034679752 hasConceptScore W2034679752C143998085 @default.
• W2034679752 hasConceptScore W2034679752C167135981 @default.
• W2034679752 hasConceptScore W2034679752C2775910329 @default.
• W2034679752 hasConceptScore W2034679752C2776694085 @default.
• W2034679752 hasConceptScore W2034679752C2777132456 @default.
• W2034679752 hasConceptScore W2034679752C2778239845 @default.
• W2034679752 hasConceptScore W2034679752C2780258809 @default.
• W2034679752 hasConceptScore W2034679752C2780352672 @default.
• W2034679752 hasConceptScore W2034679752C50382708 @default.
• W2034679752 hasConceptScore W2034679752C71924100 @default.
• W2034679752 hasConceptScore W2034679752C72563966 @default.
• W2034679752 hasConceptScore W2034679752C88879693 @default.
• W2034679752 hasConceptScore W2034679752C90924648 @default.
• W2034679752 hasIssue "8" @default.
• W2034679752 hasLocation W20346797521 @default.
• W2034679752 hasLocation W20346797522 @default.
• W2034679752 hasOpenAccess W2034679752 @default.
• W2034679752 hasPrimaryLocation W20346797521 @default.

• next